Purchase this article with an account.
U. M. Spandau, A. Wickenhäuser, F. Rensch, J. B. Jonas; Infectious and Non-Infectious Endophthalmitis After Intravitreal Bevacizumab. Invest. Ophthalmol. Vis. Sci. 2007;48(13):262.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the rate of infectious and non-infectious endophthalmitis after intravitreal injection of bevacizumab.
Clinical interventional case-series study. The study included 1218 intravitreal injections of 1.5 mg bevacizumab consecutively performed for 684 eyes with exudative age-related macular degeneration. Among the injections were 534 re-injections. Follow-up after each injection was at least 4 weeks.
One eye developed an infectious endophthalmitis 3 days after a second injection. In none of the other eyes, signs of an infectious or non-infectious endophthalmitis were observed such cellular infiltration or amorphous opacification of the vitreous, marked Tyndall phenomenon in the anterior chamber, retinal infiltration or pain.
The rate of infectious endophthalmitis after an intravitreal injection of 1.5 mf bevacizumab may be about 1:1000, similar to injections of other drugs available so far.
This PDF is available to Subscribers Only